There are three types of approaches to treating the underlying defect in CML.
The initial problem is too many white blood cells (WBCs) in the blood. A high WBC count on a blood test is often how CML is first detected.
A few years ago, CML researchers started asking themselves two intriguing questions: If imatinib and other TKIs can suppress CML to such an extent that leukemia is no longer detectable, is this a cure? And would it be possible to stop treatment altogether?
The European Treatment and Outcomes Study (EUTOS) regularly monitors how well people do in clinical trials of CML and has recently analysed data from over two thousand people to look at survival over a six-year period after diagnosis.